...
首页> 外文期刊>AJRI: American Journal of Reproductive Immunology >Massive intravenous immunoglobulin treatment in women with four or more recurrent spontaneous abortions of unexplained etiology: down-regulation of NK cell activity and subsets.
【24h】

Massive intravenous immunoglobulin treatment in women with four or more recurrent spontaneous abortions of unexplained etiology: down-regulation of NK cell activity and subsets.

机译:患有无法解释的病因的四次或以上反复自然流产的妇女的大规模静脉内免疫球蛋白治疗:NK细胞活性和亚群的下调。

获取原文
获取原文并翻译 | 示例
           

摘要

PROBLEM: The aims of this study were to investigate the efficacy of massive intravenous immunoglobulin (MIVIg) treatment for women with recurrent spontaneous abortion (RSA) of unexplained etiology, and to investigate changes in peripheral natural killer (NK) cell activity and subsets. METHOD OF STUDY: MIVIg treatment was performed in 18 pregnancies from 15 women with 4 or more consecutive RSA of unexplained etiology. NK cell activity and subsets were assessed in 8 of the pregnancies. RESULTS: 14 pregnancies resulted in live births and 4 resulted in abortions with chromosome abnormality. The pre-infusion NK cell activity (mean + SD. 40.9 + 17.0%) at 4.4 +/- 0.5 weeks of gestation (GW) decreased to 15.0 +/- 7.90% at post-infusion status (5.4 +/- 0.5 GW). Pre-infusion percentages of CD56+ CD16- cells (3.5 +/- 2.1%) and CD56+ CD16- cells (16.8 +/- 8.8%) decreased to 3.0 +/- 2.2% and 11.1 +/- 6.9%, respectively, after MIVIg treatment. CONCLUSIONS: MIVIg treatment was effective in all 14 pregnancies from RSA women of unexplained etiology, excluding 4 abortions with chromosome abnormality. Peripheral NK cell activity and subsets were suppressed by MIVIg treatment.
机译:问题:这项研究的目的是研究大规模静脉免疫球蛋白(MIVIg)治疗病因不明的反复自然流产(RSA)的妇女的有效性,并研究外周自然杀伤(NK)细胞活性和亚群的变化。研究方法:MIVIg治疗是在15名孕妇中进行的,这些孕妇来自15名患有4种或以上连续原因不明的RSA的女性。在8个怀孕中评估了NK细胞活性和亚群。结果:14例怀孕导致活产,4例导致流产且染色体异常。输注后状态(5.4 +/- 0.5 GW)时(4.4 +/- 0.5周)(GW)的输注前NK细胞活性(平均值+ SD。40.9 + 17.0%)降至15.0 +/- 7.90% 。 MIVIg后,CD56 + CD16-细胞(3.5 +/- 2.1%)和CD56 + CD16-细胞(16.8 +/- 8.8%)的预输注百分比分别降至3.0 +/- 2.2%和11.1 +/- 6.9%治疗。结论:MIVIg治疗在病因不明的RSA妇女的所有14例妊娠中均有效,但不包括4例染色体异常的流产。 MIVIg处理可抑制外周血NK细胞活性和亚群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号